Ranibizumab

SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM.MDCK cells were treated with SB 203580 to study the role of MAPK

InformationSBP-7455 (compound 26) is a dual inhibitor of ULK1 and ULK2 that potently inhibits ULK1/2 enzymatic activity in vitro and in vivo. SBP-7455 inhibits starvation-induced autophagic flux in TNBC cells.

A selective inhibitor of Plks (IC₅₀s = 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively) inhibits the proliferation of various cancer cell lines and prevents tumor growth in several human cancer cell xenograft models.

A selective inhibitor of Plks (IC₅₀s = 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively) inhibits the proliferation of various cancer cell lines and prevents tumor growth in several human cancer cell xenograft models.

A selective inhibitor of Plks (IC₅₀s = 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively) inhibits the proliferation of various cancer cell lines and prevents tumor growth in several human cancer cell xenograft models.

ApplicationTakinib has been used as an inhibitor of transforming 28 growth factor - β-activated kinase -1 (TAK-1) in human leukemia monocytic THP-1 cells. It may be used as a TAK1 inhibitor in Jurkat cells.

ApplicationTakinib has been used as an inhibitor of transforming 28 growth factor - β-activated kinase -1 (TAK-1) in human leukemia monocytic THP-1 cells. It may be used as a TAK1 inhibitor in Jurkat cells.

ApplicationTakinib has been used as an inhibitor of transforming 28 growth factor - β-activated kinase -1 (TAK-1) in human leukemia monocytic THP-1 cells. It may be used as a TAK1 inhibitor in Jurkat cells.

ApplicationTakinib has been used as an inhibitor of transforming 28 growth factor - β-activated kinase -1 (TAK-1) in human leukemia monocytic THP-1 cells. It may be used as a TAK1 inhibitor in Jurkat cells.

ApplicationTakinib has been used as an inhibitor of transforming 28 growth factor - β-activated kinase -1 (TAK-1) in human leukemia monocytic THP-1 cells. It may be used as a TAK1 inhibitor in Jurkat cells.

Vonlerolizumab (anti-OX40).

A pyrrolocarbazole compound that acts as a potent, ATP-binding site-targeting inhibitor of Wee1 (IC 50 = 59 nM) with a ~590-fold selectivity over the related checkpoint kinase Chk1 (IC 50 = 35 &#181M). Biochem/physiol Actions Cell permeable: no